The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women.
Twelve hyperprolactinemic women were administered the alpha aminoergoline derivative, CU 32-085 (Sandoz, Inc., East Hanover, NJ), in order to determine its effect on prolactin (PRL) secretion. The mean pretreatment serum PRL level was 145.0 +/- 11.5 ng/ml. Significant declines of serum PRL occurred with total daily doses of CU 32-085 of 0.1 to 0.5 mg (P less than 0.001). The magnitude of response to therapy was dose-related. In six patients, PRL levels were reduced to less than 25 ng/ml; this effect lasted at least 24 hours after intake of a single dose. In the other six patients, the response was less dramatic. No subjects developed adverse cardiovascular side effects. The results of this study demonstrate that CU 32-085 exhibits a clinically significant dopaminomimetic action on PRL secretion in hyperprolactinemic women.
D000236:Adenoma / Q000150:complications; D000328:Adult; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D007700:Kinetics; D008599:Menstruation Disturbances / Q000188:drug therapy; D010911:Pituitary Neoplasms / Q000150:complications; D011388:Prolactin / Q000378:metabolism*
D004873:Ergolines; D011388:Prolactin; C031649:mesulergine